Exelixis | EXEL - Sales Revenues


Exelixis reported $598.66M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Akebia Therapeutics USD 57.34M 10.84M Mar/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bayer EUR 11.44B 1.78B Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Cytokinetics USD 17.76M 15.83M Dec/2025
Eisai JPY 219.94B 22.58B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Exelixis USD 598.66M 860K Dec/2025
Genmab DKK 5.86B 580M Jun/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Incyte USD 1.51B 140M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 678M 342M Dec/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sanofi EUR 12.2B 3.19B Dec/2025
Takeda JPY 1.19T 80B Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025